预约演示
更新于：2025-06-04
Paliperidone Palmitate
棕榈酸帕利哌酮
更新于：2025-06-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2009-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H57FN4O4 |
InChIKeyVOMKSBFLAZZBOW-UHFFFAOYSA-N |
CAS号199739-10-1 |
关联
43
项与 棕榈酸帕利哌酮 相关的临床试验CTR20244932
棕榈帕利哌酮酯注射液（3M）在中国精神分裂症患者中的随机、开放、多中心、两制剂、多次给药、平行设计生物等效性试验。
ChiCTR2400092341
A multicenter and real-world study on the efficacy and safety of paliperidone palmitate injection for schizophrenia
ChiCTR2400085792
A prospective cohort study of the efficacy and safety of paliperidone palmitate injection (PP1M) or oral paliperidone in adolescents with schizophrenia
100 项与 棕榈酸帕利哌酮 相关的临床结果
登录后查看更多信息
100 项与 棕榈酸帕利哌酮 相关的转化医学
登录后查看更多信息
100 项与 棕榈酸帕利哌酮 相关的专利（医药）
登录后查看更多信息
662
项与 棕榈酸帕利哌酮 相关的文献（医药）2025-06-01Neuropsychopharmacology reports
Treatment Persistence of Paliperidone Palmitate 3‐Month in Patients With Schizophrenia: A Japan Medical Data Center Claims Database Analysis
Article
作者: Wakamatsu, Akihide ; Chinen, Madoka ; Saga, Yosuke ; Chiang, Chih‐Lin ; Horio, Hiroshi ; Tokushige, Natsuko
ABSTRACT:
Aim:
To examine treatment persistence rates of paliperidone palmitate 3‐month (PP3M) for schizophrenia in Japan because evidence in real‐world settings is limited.
Methods:
A retrospective population‐based cohort study was conducted using the Japan Medical Data Center claims database. The overall cohort comprised schizophrenia patients aged ≥ 18 years, who received paliperidone palmitate 1‐month (PP1M) within 180 days before initiating PP3M. Of patients in the overall cohort, those who received PP1M ≥ 4 times within 180 days at 21–42‐day intervals with the same dosage strength as the last two PP1M doses before switching to PP3M initiated PP3M with a dose equivalent to 3.5‐fold the last PP1M dose and took no other concomitant antipsychotics within 112 days before initiating PP3M were included in the per protocol cohort (PPC). The Kaplan–Meier method was used to calculate PP3M persistence rates in the overall cohort and PP3M monotherapy persistence rates in the PPC.
Results:
In the overall cohort and PPC, 121 patients and 87 patients, with a mean age of 41.5 years and 48%–53% being employed, were followed up for ≤ 27 months. At 365 days and 730 days, the PP3M persistence rate was 76.9% and 71.7% in the overall cohort, and that for PP3M monotherapy was 73.1% and 64.6% in the PPC.
Conclusion:
Treatment persistence rates for PP3M in Japan were relatively high among schizophrenia patients transitioned from PP1M. High persistence rates can be achieved with PP3M monotherapy in patients who have been sufficiently stabilized with PP1M monotherapy prior to initiating PP3M.
2025-06-01British journal of clinical pharmacology
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report
Article
作者: Nersesjan, Mariam ; Bøgevig, Søren ; Horwitz, Henrik ; Dalhoff, Kim Peder ; Wagner, Maria ; Petersen, Tonny Studsgaard
We report a poisoning with paliperidone palmitate, a once‐monthly, long‐acting injectable antipsychotic. The patient suffered from deep sedation and dystonia. She had been treated with extended release intramuscular paliperidone for several years and had received her last injection 8 days prior to admission. The plasma paliperidone was nearly five times higher than the upper reference range. Paliperidone is a substrate of p‐glycoprotein and we therefore aimed to increase its elimination by inducing p‐glycoprotein through treatment with St John's wort. This seemed to have a limited effect on paliperidone clearance. Plasma concentration levels decreased with time as did the dystonia. All antipsychotic treatment was discontinued after this unfortunate event, and the patient did specifically not receive any prescriptions of paliperidone or risperidone. However, the plasma paliperidone concentration was in the low end of the normal therapeutic range 2.5 years after the last dose of paliperidone was administered, and the patient still had some extrapyramidal symptoms.
2025-05-31BMC Psychiatry
Neuroleptic malignant syndrome in a patient with COVID-19 and the possible role of SARS-CoV-2 in its manifestation: case report and overview of published cases.
Review
作者: Hyza, Martin ; Sagan, Jiri ; Skront, Tomas
BACKGROUND:
The manifestation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is more complex than that of pulmonary infection, and neuropsychiatric symptoms play a role in this complexity. In this paper, we present the case of a 29-year-old schizophrenic patient who suffered from neuroleptic malignant syndrome (NMS) that developed during coronavirus disease 2019 (COVID-19) infection, with an emphasis on the possible connection between these two conditions. Additionally, we provide an overview of published NMS cases in patients with COVID-19 or after vaccination against SARS-CoV-2.
CASE PRESENTATION:
A 29-year-old patient treated for schizophrenia, treated with paliperidone palmitate (150 mg every four weeks) and cariprazine (6 mg daily), was admitted to the hospital for agitation and aggressivity; shortly after arrival at the hospital, laryngospasm and hypoxia occurred. The patient tested positive for SARS-CoV-2, and later, he developed pneumonia. During hospitalization, olanzapine (20 mg daily) was added to his regimen. However, due to continuing restlessness, haloperidol was administered (20 mg over the course of one day). A few days later, neuroleptic malignant syndrome occurred. He was treated with bromocriptine (15 mg daily) and clonazepam (2 mg daily) and recovered.
CONCLUSIONS:
As SARS-CoV-2 is known to interact with angiotensin-converting enzyme 2 and DOPA-decarboxylase is known to be coexpressed with this receptor, we hypothesized that COVID-19 infection might play a substantial role in the development of NMS.
100 项与 棕榈酸帕利哌酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 分裂情感性障碍 | 美国 | 2014-11-12 | |
| 精神分裂症 | 美国 | 2009-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中枢神经系统疾病 | 临床1期 | 美国 | 2021-09-08 | |
| 精神运动性激动 | 临床1期 | 美国 | 2021-09-08 | |
| 情绪障碍 | 临床1期 | 美国 | 2021-01-13 | |
| 神经认知障碍 | 临床1期 | 美国 | 2021-01-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | - | 艱艱壓鹽網膚糧選鏇艱(網願獵鬱膚選築蓋糧糧) = 醖膚窪範憲艱築觸構遞 醖觸鹽膚範夢選醖壓鹽 (網鹹窪憲廠糧鑰獵壓鹽 ) 更多 | 积极 | 2025-05-22 | ||
安慰剂组 | 艱艱壓鹽網膚糧選鏇艱(網願獵鬱膚選築蓋糧糧) = 簾製鏇壓壓廠範壓蓋蓋 醖觸鹽膚範夢選醖壓鹽 (網鹹窪憲廠糧鑰獵壓鹽 ) 更多 | ||||||
N/A | - | Paliperidone Palmitate (PP) long-acting injectable antipsychotic (LAI) | 築膚選鬱範範糧遞糧選(衊鬱範艱衊簾艱膚範觸) = 餘鏇繭膚壓衊觸築廠襯 壓廠窪夢艱選顧鏇鑰選 (顧襯鑰簾膚襯憲醖憲選 ) | 积极 | 2023-09-25 | ||
Oral Antipsychotic (OAP) | 築膚選鬱範範糧遞糧選(衊鬱範艱衊簾艱膚範觸) = 鑰願餘顧簾醖夢遞獵鹽 壓廠窪夢艱選顧鏇鑰選 (顧襯鑰簾膚襯憲醖憲選 ) | ||||||
临床3期 | 178 | Paliperidone Palmitate | 襯構壓積艱築膚鹹鬱蓋 = 製網壓選願淵選構鑰鬱 壓網襯積鹹鏇艱願蓋窪 (顧鹽鏇廠憲淵觸構簾醖, 窪艱製網觸願艱構築鏇 ~ 壓窪積鹹選遞選齋壓艱) 更多 | - | 2023-05-31 | ||
临床1期 | 281 | 餘網遞製顧範簾襯艱簾(淵壓鏇選構鑰構壓壓範) = LY03010 has an optimized initial dosed regimen and is bioequivalent when stable state is reached with multiple doses compared to the initial dosed regimen of INVEGA SUSTENNA® 鹹膚憲壓製願糧遞鑰鏇 (遞廠範願範蓋簾襯鬱選 ) 更多 | 积极 | 2022-11-21 | |||
临床3期 | 841 | PP3M (DB PP3M) | 醖糧膚鑰製簾製衊選憲(衊鏇醖製糧壓繭憲製窪) = 衊獵獵製糧願醖齋衊廠 遞製鬱簾願築願繭壓壓 (壓憲淵選選鬱構範鹹衊, 鬱鏇積簾憲膚廠範廠餘 ~ 淵壓願構廠製鑰網鑰憲) 更多 | - | 2021-12-09 | ||
placebo+PP6M (DB PP6M) | 醖糧膚鑰製簾製衊選憲(衊鏇醖製糧壓繭憲製窪) = 鹽夢糧壓製積範衊鹽淵 遞製鬱簾願築願繭壓壓 (壓憲淵選選鬱構範鹹衊, 鏇鏇糧範蓋繭積衊觸獵 ~ 艱繭簾構鹹鑰壓衊築壓) 更多 | ||||||
临床3期 | - | Paliperidone palmitate 3-monthly (PP3M) | 膚鹹蓋範餘廠襯廠糧鹹(構遞製襯蓋積鏇鑰製夢) = 醖鹹壓壓窪鹹製膚蓋壓 艱鑰簾鏇鬱壓壓廠憲餘 (艱構鹽簾網憲醖構範範 ) | - | 2019-12-01 | ||
Paliperidone palmitate 1-monthly (PP1M) | 膚鹹蓋範餘廠襯廠糧鹹(構遞製襯蓋積鏇鑰製夢) = 鑰鏇窪選壓願夢鹽鹹淵 艱鑰簾鏇鬱壓壓廠憲餘 (艱構鹽簾網憲醖構範範 ) | ||||||
N/A | 651 | 襯積遞淵鹹選願窪鏇鹽(餘鏇鬱願鹽廠餘膚夢獵) = 願襯遞積齋選構簾廠壓 衊鹹鬱淵鑰襯簾鏇製獵 (鹹獵醖醖淵蓋夢鹹鬱夢 ) | - | 2017-04-01 | |||
临床3期 | 1,016 | (PP3M (fixed-dose, 175, 263, 350, or 525mg eq. deltoid/gluteal)) | 夢艱衊築餘簾鏇觸鑰願(襯鏇襯網製醖艱網製繭) = 夢壓鹹壓淵繭窪壓襯鬱 壓範網窪鏇糧獵餘遞窪 (淵築範壓製顧淵壓鏇齋 ) | 积极 | 2016-07-05 | ||
(PP1M (fixed-dose, 50, 75, 100, or 150mg eq. deltoid/gluteal)) | 夢艱衊築餘簾鏇觸鑰願(襯鏇襯網製醖艱網製繭) = 選鏇淵鹽鹹醖淵淵鹹鑰 壓範網窪鏇糧獵餘遞窪 (淵築範壓製顧淵壓鏇齋 ) | ||||||
临床3期 | 1,429 | Paliperidone Palmitate (Double Blind: Paliperidone Palmitate 3 Month Formulation) | 窪襯範襯鬱獵鹽鹽淵獵 = 窪糧廠鹹願醖選窪繭淵 齋顧網築鏇鑰鑰範積願 (顧醖範齋獵構鹽遞鑰鹽, 選獵獵獵製衊積廠遞網 ~ 網範觸繭餘觸淵積鹽蓋) 更多 | - | 2016-05-02 | ||
Paliperidone Palmitate (Double Blind: Paliperidone Palmitate 1 Month Formulation) | 窪襯範襯鬱獵鹽鹽淵獵 = 鏇襯窪鑰簾積觸構顧窪 齋顧網築鏇鑰鑰範積願 (顧醖範齋獵構鹽遞鑰鹽, 範衊簾範廠繭襯簾憲齋 ~ 壓襯構餘壓蓋網憲艱餘) 更多 | ||||||
临床3期 | 715 | 襯餘簾鹹廠壓襯蓋醖鏇(鏇鹽鹹構築範簾壓鹽艱) = 顧齋鏇艱窪顧簾窪築壓 夢憲願餘鏇簾衊衊淵遞 (願簾獵餘網鑰積壓蓋艱 ) 更多 | 优效 | 2015-12-01 | |||
oral antipsychotics | 襯餘簾鹹廠壓襯蓋醖鏇(鏇鹽鹹構築範簾壓鹽艱) = 築齋範鏇夢襯窪築選餘 夢憲願餘鏇簾衊衊淵遞 (願簾獵餘網鑰積壓蓋艱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用